Anti Cd 20 Ocrevus denied as experimental or investigational by Aetna?

Aetna's specific coverage criteria for anti cd20 ocrevus are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Ocrevus as Experimental

An experimental or investigational denial from Aetna for Ocrevus (ocrelizumab) is unusual but does occur in two scenarios: the requested use falls outside the FDA-approved label (an off-label indication), or Aetna's clinical policy has not yet been updated to reflect a newer approval. Ocrevus holds FDA approval for both relapsing forms of MS and primary progressive MS — it was the first therapy ever approved for PPMS — so a denial on experimental grounds for an on-label indication is highly vulnerable to appeal.

If the requested use is on-label, this denial is likely based on a clerical mismatch between the submitted diagnosis code and Aetna's benefit criteria, and it should be corrected through appeal.

## Federal Appeal Rights

• Internal appeal: File under ERISA §503 (employer plan) or ACA internal-review rules (marketplace/individual plan). Deadlines are printed on the denial letter — act promptly.
• External review: Under ACA §2719, experimental-or-investigational denials are explicitly subject to external review by an Independent Review Organization. This is one of the most favorable categories for enrollees because the IRO applies objective medical evidence standards rather than Aetna's internal policy.
• Expedited option: Available when delayed care poses a serious health risk; ask your neurologist to certify urgency in writing.

## What to Gather

1. FDA approval documentation — print the current FDA label for ocrelizumab from DailyMed (dailymed.nlm.nih.gov). Highlight the approved indication that matches your diagnosis. 2. Diagnosis confirmation — neurology notes with MS subtype (relapsing or primary progressive), MRI evidence of disease activity or progression, and functional status. 3. Relevant guideline endorsement — a statement from your neurologist referencing the applicable professional society guideline (such as those from the American Academy of Neurology or the National MS Society) that supports ocrelizumab for this patient's MS subtype and disease stage. 4. Prescriber medical-necessity letter — explicitly connecting the approved indication to this patient's documented diagnosis, and rebutting the experimental characterization with reference to the FDA label.

## Criteria-Mapping Structure

| Aetna Policy Requirement | Supporting Documentation | |---|---| | Therapy is FDA-approved for submitted indication | FDA label excerpt + diagnosis code match | | Diagnosis confirmed as relapsing MS or PPMS | Neurologist note + MRI | | Not an investigational use | FDA label approval date; guideline endorsement | | Meets all other clinical criteria in policy bulletin | Map each criterion to chart entry |

Attach the FDA label as Exhibit A. Lead your appeal letter with the sentence: "Ocrelizumab is FDA-approved for [patient's exact diagnosis]. This is not an experimental use."